Bactiguard’s Q3 net sales of SEK 55m came in +8% vs SEB (SEK 51m). Recurring license revenue key highlight and amounted to SEK 41m (SEBe: SEK 33m) with BD specifically amounting to SEK 38m (SEBe: SEK 30m). This was more than offsetting a weaker Wound Management performance. Q3 adj. EBITDA was SEK 20m vs. SEBe at SEK 5m indicating lower expenses as well. Overall, a solid report for the base business we believe.
